Detralex, 1000 mg/10 ml suspension 10 ml 30 pcs

Detralex® has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indexes of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex® has been demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, and time of venous emptying. An optimal dose-effect ratio was observed with administration of 1000 mg/day.

Detralex® increases venous tone: venous occlusion plethysmography has shown a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders after therapy with Detralex® a statistically significant (in comparison with placebo) increase of capillary resistance evaluated by angiostereometry was noted.

Therapeutic effectiveness of Detralex® has been proven in the treatment of chronic diseases of lower limb veins and in the treatment of hemorrhoids.

Detralex® reduces undesirable side effects of invasive methods of treatment of chronic venous diseases (it reduces frequency of undesirable side effects of surgical and endovascular treatment of varicose veins: intensity of postoperative pain syndrome, edema and severity of bleeding after endovascular and surgical treatment reduces significantly).

Pharmacokinetics

The main excretion of the drug is with the feces. With urine, on average, about 14% of the administered amount of the drug is excreted. T1/2 is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Indications

Detralex® is indicated for the treatment of symptoms of chronic vein disease (elimination and relief of symptoms).

The therapy of symptoms of venous and lymphatic insufficiency:

– pain;

– cramping of the lower extremities;

– feeling of heaviness and tumescence in the legs;

– “tired” legs.

Treatment of manifestations of venous and lymphatic insufficiency:

– swelling of the lower extremities;

– trophic changes in the skin and subcutaneous tissue;

– venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Composition

1 sachet (10 ml)

Purified micronized flavonoid fraction 1000 mg, including. Diosmin 900 mg (90%), flavonoids in terms of hesperidin100 mg (10%)

Excipients:

citric acid – 12.5 mg,

Orange flavoring – 15 mg,

maltitol – 1800 mg,

sodium benzoate – 15 mg,

xanthan gum – 50 mg,

purified water q.s. – up to 10 ml.

How to take, the dosage

The drug is taken orally.

The recommended dose for venous lymphatic insufficiency is 1000 mg (contents of 1 sachet)/day, preferably in the morning, with a meal.

The duration of treatment can be several months (up to 12 months). If symptoms recur, the course of treatment may be repeated upon a physician’s recommendation.

The recommended dose in acute hemorrhoids is 3000 mg/day (1000 mg (contents of 1 sachet) in the morning, afternoon and evening) for 4 days, then 2000 mg/day (1000 mg (contents of 1 sachet) in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1000 mg (contents of 1 sachet)/day at any convenient time of day along with a meal.

Interaction

No drug interactions of the drug Detralex® have been reported.

The patient should inform the attending physician about all medications taken.

Special Instructions

It is recommended that the patient consult a physician before starting the use of the drug Detralex®.

In case of exacerbation of hemorrhoids, administration of the drug Detralex® does not replace specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Dosage regimen”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will choose further therapy.

In the presence of venous circulatory disorders, the maximum effect of treatment is achieved by combining therapy with a healthy (balanced) lifestyle; it is advisable to avoid long periods of exposure to the sun, prolonged exposure to the sun, and reduction of excessive body weight. Walking and, in some cases, wearing special stockings (compression stockings) improves circulation.

The patient should see a physician immediately if the condition worsens or does not improve with treatment.

Impact on ability to drive and operate machinery

The drug does not affect the ability to drive and perform work requiring high mental and physical speed.

Contraindications

– hypersensitivity to the active ingredient or excipients contained in the drug;

– fructose intolerance.

The drug is not recommended for breastfeeding women.

Side effects

The side effects of the drug Detralex® observed during clinical trials were mild in severity. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were mostly observed.

When taking Detralex® the following side effects have been reported in the following gradation: very frequently (>1/10), frequently (>1/100,1/1000,1/10,000, >1/100,1/10,000),

CNS side effects: rarely – dizziness, headache, general malaise.

Gastrointestinal disorders: frequent – diarrhea, dyspepsia, nausea, vomiting; infrequent – colitis; unspecified frequency – abdominal pain.

The skin: rare – skin rash, pruritus, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema.

The patient should inform the physician about the occurrence of any, including those not mentioned in the instructions, adverse reactions and sensations, as well as about changes in laboratory parameters during therapy.

Overdose

No cases of overdose have been described.

Patients should seek medical attention immediately if they overdose.

Similarities